Detail Article

Folia Medica Indonesiana

ISSN 0303-7932

Vol. 44 / No. 1 / Published : 2008-01

Order : 12, and page :56 - 59

Related with : Scholar   Yahoo!   Bing

Original Article :

Treatment response of chronic myelogenic leukemia in dr. soetomo hospital

Author :

  1. Ugroseno*1
  1. Hematology and Medical Oncology Division, Department of Internal Medicine Airlangga University School of Medicine, Dr Soetomo Teaching Hospital, Jl Prof Dr Moestopo 6-8, Surabaya

Abstract :

Chronic myelogenic leukemia is the most frequent hematology malignancies in adult. In the US, the frequency of CML is about 15% of all hematological malignancies. The incidence was 1-2 : 100.000, with male and female 1.3 : 1, and it increases associated with age 45-55 year. In Internal Medicine Department, Airlangga University School of Medicine, Dr. Soertomo Hospital, Surabaya, CML is the most frequent hematological malignancy after malignant lymphoma. The diagnosis was established by clinical festures such as organomegaly, leukocytosis and bone marrow aspiration. CML treatment includes supportive therapy, chemoteraphy, and stem cell transplantation. The cheaper and frequently used chemotheraphy are busulfan and hydroxyurea, but the response is not satisfying. In CML patient with positive Philadelphia chromosome, treatment with imatinib gives response rate about 90-95%. The purpose of this study was to find out the response of hyrea, busulfan and imatinib therapy on CML. Sample of this study was the patient in Medical Oncology and Hematology Outpatient Clinic of Dr. Soetomo Hospital, from January 1, 2004, to December, 31, 2006. Along this time there were 58 patients with CML. Twenty eight patients were females and the rests were male. The response of patient with myeleran showed that three patients had complete remission. Among those receiving hydroxyurea 6,6 % showed partial remision, and 79.9% patients showed complete remission treatment by imatinib.

Keyword :

hematology malignancies, chronic myelogenic leukemia, hyrea, busulfan, imatinib, Dr Soetomo Hospital,

References :

  1. Druker, BJ, Guilhot, F, O’Brien, SG, (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia . - : N Engl J of Med
  2. Faderl, S, Talpaz, M, Estrov, Z, Kantarjian, HM, (1999). Chronic myelogenous leukemia: Biology and therapy . - : Annals of Internal Medicine

Archive Article

Cover Media Content

Volume : 44 / No. : 1 / Pub. : 2008-01
  1. Correlation between dengue virus serotype and humoral immune response in pediatric dengue hemorrhagic fever
  2. Modulation of immunoglobulin g (igg) and cortisol responses in breathing exercise
  3. Prediction of distribution pattern of aedes aegypti as dhf main vector in jember
  4. Difference of interferon gammalevel (release assay) in nurses exposed to mycobacterium tuberculosis and active tuberculous patients
  5. Molecular expression of estrogen receptor alpha (erα) and interleukin 6 (il-6) on acceleration of healing process of long bone shaft fracture by immediate repetitive axial compression tension stabilization (ireact)
  6. Il-4 in peripheral blood mononuclear cells and bronchoalveolar lavage patients with pulmonary tuberculosis before and after treatment with oral anti-tuberculosis drugs
  7. Effect of oral curcumin and immobilization on the diameter of skeletal muscle fiber in rattus norvegicus
  8. Contralateral renal fibroblast and tubular cell apoptosis and proliferation in artificial unilateral total urethral obstruction in rabbits
  9. Polymorphism c3435t of the mdr-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer with her2/neu expression
  10. Review article:challenge of environmental toxicology in reformation era
  11. Bone morphogenetic protein 4 (bmp4) and prostaglandin alpha (pge2α) molecular expression in healing process acceleration of long bone shaft fracture using immediate repetitive axial compression tension stabilization (ireact)
  12. Treatment response of chronic myelogenic leukemia in dr. soetomo hospital
  13. Review article and clinical experience:the obesity pandemic: the “time-bomb disease” in the future?where have we been? and what should we do?